SLS
SELLAS Life Sciences Group, Inc.
$12.76
-0.75 (-5.55%)
At close · Jul 10
Market Cap
$2.37B
Shares
186,032,574
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.76
Open$13.27
Day$12.49–13.36
52W$1.39–15.88
Avg vol 30d10.7M
Short int63.3M · 34.0% float · 4.8d
Short vol60%
Last earningsMay 27, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
Next earnings call
May 26, 2027
Est · unconfirmed
· in 45 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+174%
above
Price vs 50-day avg
+47%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+78%
trailing
6-month return
+232%
trailing
YTD return
+238%
this year
Relative strength
+223%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $5 — 50d above 200d
Institutional flow
Distributing
5 of 164 funds reported for Jun 30 · net -75.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
34.03% of float · ▼ -0.1% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+50%
Y/Y
Free cash flow
$-28.4M
Balance sheet
$60.8M
net cash
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−36%
past year
ATR
11.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+174%
Bullish
Price vs 50-day avg
+47%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $5 — 50d above 200d
Institutional flow
Distributing
5 of 164 funds reported for Jun 30 · net -75.9K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
34.03% of float · ▼ -0.1% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
164 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $13 · 78%
52-wk high $16
vs 200-day avg +174%
vs 50-day avg +47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLS
this stock
SELLAS Life Sciences Group, Inc.
|
$2.37B | +238.5% | -86.8% | — | 34.0% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLS | -14.8% | +78.5% | +232.3% | -13.6% | +238.5% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -16.2% | +74.4% | +223.2% | -14.7% | +227.8% |
Key facts
CIK
1390478
CUSIP
81642T209
13F (30d)
12 filings
6 filers
Visit website
Investor relations